Transgene SA (TNG.PA)
EUR 0.6
(-1.63%)
EUR 0.6
(-1.63%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -28.4 Million EUR | 2.2% |
| 2022 | -29.04 Million EUR | -26.88% |
| 2021 | -22.89 Million EUR | 6.05% |
| 2020 | -24.36 Million EUR | 1.49% |
| 2019 | -24.73 Million EUR | 4.9% |
| 2018 | -26 Million EUR | -306.3% |
| 2017 | -6.4 Million EUR | -2171.52% |
| 2016 | 309 Thousand EUR | 126.39% |
| 2015 | -1.17 Million EUR | 90.79% |
| 2014 | -12.71 Million EUR | -1.27% |
| 2013 | -12.55 Million EUR | -14.39% |
| 2012 | -10.97 Million EUR | 71.58% |
| 2011 | -38.6 Million EUR | -35.88% |
| 2010 | -28.4 Million EUR | -33.61% |
| 2009 | -21.26 Million EUR | -16.04% |
| 2008 | -18.32 Million EUR | -2249.1% |
| 2007 | -780 Thousand EUR | 95.81% |
| 2006 | -18.6 Million EUR | 0.0% |
| 2004 | 2.51 Million EUR | 0.52% |
| 2003 | 2.5 Million EUR | 13.37% |
| 2002 | 2.2 Million EUR | 75.08% |
| 2001 | 1.26 Million EUR | -73.33% |
| 2000 | 4.72 Million EUR | 9.23% |
| 1999 | 4.32 Million EUR | -57.32% |
| 1998 | 10.13 Million EUR | 90.05% |
| 1997 | 5.33 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 23 Thousand EUR | 0.0% |
| 2023 Q1 | -5.4 Million EUR | 20.18% |
| 2023 Q4 | -5.44 Million EUR | 0.0% |
| 2023 Q3 | -5.44 Million EUR | 17.92% |
| 2023 Q2 | -6.62 Million EUR | -22.68% |
| 2023 FY | -28.4 Million EUR | 2.2% |
| 2022 Q2 | -6.18 Million EUR | -13.7% |
| 2022 Q1 | -5.44 Million EUR | -3788.21% |
| 2022 Q4 | -6.76 Million EUR | -23.78% |
| 2022 FY | -29.04 Million EUR | -26.88% |
| 2022 Q3 | -5.46 Million EUR | 11.64% |
| 2021 Q3 | -2.64 Million EUR | 58.04% |
| 2021 FY | -22.89 Million EUR | 6.05% |
| 2021 Q2 | -6.3 Million EUR | -21.9% |
| 2021 Q4 | -140 Thousand EUR | 94.71% |
| 2021 Q1 | -5.17 Million EUR | 14.2% |
| 2020 Q1 | -4.3 Million EUR | -35.68% |
| 2020 Q4 | -6.03 Million EUR | -31.52% |
| 2020 Q3 | -4.58 Million EUR | 1.6% |
| 2020 Q2 | -4.66 Million EUR | -8.37% |
| 2020 FY | -24.36 Million EUR | 1.49% |
| 2019 Q4 | -3.16 Million EUR | 20.92% |
| 2019 Q3 | -4 Million EUR | 31.73% |
| 2019 FY | -24.73 Million EUR | 4.9% |
| 2019 Q1 | -5.03 Million EUR | -1.38% |
| 2019 Q2 | -5.87 Million EUR | -16.57% |
| 2018 FY | -26 Million EUR | -306.3% |
| 2018 Q1 | -5.16 Million EUR | -1505.29% |
| 2018 Q2 | -5.16 Million EUR | 0.0% |
| 2018 Q4 | -4.96 Million EUR | 0.0% |
| 2018 Q3 | -4.96 Million EUR | 3.74% |
| 2017 Q3 | -321.5 Thousand EUR | -60.75% |
| 2017 Q1 | -200 Thousand EUR | -751.06% |
| 2017 Q2 | -200 Thousand EUR | 0.0% |
| 2017 FY | -6.4 Million EUR | -2171.52% |
| 2017 Q4 | -321.5 Thousand EUR | 0.0% |
| 2016 Q2 | 587.5 Thousand EUR | 0.0% |
| 2016 Q1 | 587.5 Thousand EUR | 718.42% |
| 2016 Q3 | -23.5 Thousand EUR | -104.0% |
| 2016 FY | 309 Thousand EUR | 126.39% |
| 2016 Q4 | -23.5 Thousand EUR | 0.0% |
| 2015 Q3 | -95 Thousand EUR | -116.45% |
| 2015 Q2 | 577.5 Thousand EUR | 0.0% |
| 2015 Q4 | -95 Thousand EUR | 0.0% |
| 2015 FY | -1.17 Million EUR | 90.79% |
| 2015 Q1 | 577.5 Thousand EUR | 161.6% |
| 2014 FY | -12.71 Million EUR | -1.27% |
| 2014 Q4 | -937.5 Thousand EUR | 0.0% |
| 2014 Q3 | -937.5 Thousand EUR | 15.77% |
| 2014 Q2 | -1.11 Million EUR | 0.0% |
| 2014 Q1 | -1.11 Million EUR | -371.13% |
| 2013 Q2 | -742.99 Thousand EUR | 0.0% |
| 2013 FY | -12.55 Million EUR | -14.39% |
| 2013 Q4 | 410.5 Thousand EUR | 0.0% |
| 2013 Q1 | -742.99 Thousand EUR | -62.76% |
| 2013 Q3 | 410.5 Thousand EUR | 155.25% |
| 2012 Q4 | -456.5 Thousand EUR | 0.0% |
| 2012 Q3 | -456.5 Thousand EUR | 0.0% |
| 2012 FY | -10.97 Million EUR | 71.58% |
| 2011 FY | -38.6 Million EUR | -35.88% |
| 2010 FY | -28.4 Million EUR | -33.61% |
| 2009 FY | -21.26 Million EUR | -16.04% |
| 2008 FY | -18.32 Million EUR | -2249.1% |
| 2007 FY | -780 Thousand EUR | 95.81% |
| 2006 FY | -18.6 Million EUR | 0.0% |
| 2005 Q2 | 1.08 Million EUR | 7.35% |
| 2005 Q1 | 1.01 Million EUR | 42.1% |
| 2004 Q2 | 434.8 Thousand EUR | -33.46% |
| 2004 Q1 | 653.43 Thousand EUR | 4.45% |
| 2004 Q3 | 832.52 Thousand EUR | 91.47% |
| 2004 Q4 | 713.68 Thousand EUR | -14.27% |
| 2004 FY | 2.51 Million EUR | 0.52% |
| 2003 FY | 2.5 Million EUR | 13.37% |
| 2003 Q4 | 625.59 Thousand EUR | 12.43% |
| 2003 Q2 | 424.08 Thousand EUR | -52.63% |
| 2003 Q3 | 556.43 Thousand EUR | 31.21% |
| 2003 Q1 | 895.34 Thousand EUR | -43.86% |
| 2002 Q4 | 1.59 Million EUR | 281.64% |
| 2002 FY | 2.2 Million EUR | 75.08% |
| 2002 Q1 | 82.53 Thousand EUR | -76.33% |
| 2002 Q2 | 110.36 Thousand EUR | 33.73% |
| 2002 Q3 | 417.88 Thousand EUR | 278.63% |
| 2001 Q3 | 137.25 Thousand EUR | -18.74% |
| 2001 Q1 | 602.94 Thousand EUR | -63.47% |
| 2001 FY | 1.26 Million EUR | -73.33% |
| 2001 Q4 | 348.61 Thousand EUR | 153.98% |
| 2001 Q2 | 168.91 Thousand EUR | -71.99% |
| 2000 Q2 | 1.7 Million EUR | 134.44% |
| 2000 Q4 | 1.65 Million EUR | 162.92% |
| 2000 FY | 4.72 Million EUR | 9.23% |
| 2000 Q3 | 627.81 Thousand EUR | -63.24% |
| 2000 Q1 | 728.41 Thousand EUR | -14.38% |
| 1999 Q3 | 751.18 Thousand EUR | -40.41% |
| 1999 FY | 4.32 Million EUR | -57.32% |
| 1999 Q4 | 850.77 Thousand EUR | 13.26% |
| 1999 Q1 | 1.48 Million EUR | -57.2% |
| 1999 Q2 | 1.26 Million EUR | -14.94% |
| 1998 FY | 10.13 Million EUR | 90.05% |
| 1998 Q1 | 7.94 Million EUR | 0.0% |
| 1998 Q2 | 646.03 Thousand EUR | -91.87% |
| 1998 Q3 | 427.27 Thousand EUR | -33.86% |
| 1998 Q4 | 3.46 Million EUR | 710.45% |
| 1997 FY | 5.33 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | 4696.117% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 825.703% |
| Adocia SA | 1.38 Million EUR | 2150.83% |
| Aelis Farma SA | 12.35 Million EUR | 329.843% |
| Biophytis S.A. | -803 Thousand EUR | -3437.235% |
| Advicenne S.A. | 1.42 Million EUR | 2091.865% |
| genOway Société anonyme | 20.1 Million EUR | 241.311% |
| IntegraGen SA | 5.01 Million EUR | 666.011% |
| Medesis Pharma S.A. | -2.66 Million EUR | -965.909% |
| Neovacs S.A. | 29.31 Thousand EUR | 96995.681% |
| NFL Biosciences SA | -56.06 Thousand EUR | -50563.527% |
| Plant Advanced Technologies SA | 2.15 Million EUR | 1419.326% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | -1901.284% |
| Sensorion SA | 3.78 Million EUR | 849.869% |
| Theranexus Société Anonyme | -4.63 Million EUR | -512.328% |
| TME Pharma N.V. | -127 Thousand EUR | -22265.354% |
| Valbiotis SA | 2.66 Million EUR | 1164.618% |
| TheraVet SA | -530.79 Thousand EUR | -5251.208% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | 2341.831% |
| DBV Technologies S.A. | 4.15 Million EUR | 782.855% |
| Genfit S.A. | 28.22 Million EUR | 200.638% |
| GeNeuro SA | -293.8 Thousand EUR | -9567.801% |
| Innate Pharma S.A. | -4.12 Million EUR | -589.25% |
| Inventiva S.A. | 17.5 Million EUR | 262.309% |
| MaaT Pharma SA | 1.65 Million EUR | 1816.254% |
| MedinCell S.A. | 9.28 Million EUR | 405.814% |
| Nanobiotix S.A. | 36.2 Million EUR | 178.447% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 1375.438% |
| Poxel S.A. | 1000.00 EUR | 2840500.0% |
| GenSight Biologics S.A. | 3 Million EUR | 1046.8% |
| Valneva SE | 52.83 Million EUR | 153.758% |